JP2007534615A - Ｈｉｖ免疫原性複合体 - Google Patents

Ｈｉｖ免疫原性複合体 Download PDF

Info

Publication number
JP2007534615A
JP2007534615A JP2006517744A JP2006517744A JP2007534615A JP 2007534615 A JP2007534615 A JP 2007534615A JP 2006517744 A JP2006517744 A JP 2006517744A JP 2006517744 A JP2006517744 A JP 2006517744A JP 2007534615 A JP2007534615 A JP 2007534615A
Authority
JP
Japan
Prior art keywords
complex
hiv
antibody
antibodies
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006517744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534615A5 (enExample
Inventor
パル ラナジト
マルクハム フィリップ
ケエン チモシー
ウヒトネイ ステプヘン
エス． カルヤナラマン ブイ．
Original Assignee
アドバンスド バイオサイエンシーズ ラボラトリーズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドバンスド バイオサイエンシーズ ラボラトリーズ インコーポレーテッド filed Critical アドバンスド バイオサイエンシーズ ラボラトリーズ インコーポレーテッド
Publication of JP2007534615A publication Critical patent/JP2007534615A/ja
Publication of JP2007534615A5 publication Critical patent/JP2007534615A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006517744A 2003-07-02 2004-06-28 Ｈｉｖ免疫原性複合体 Pending JP2007534615A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/612,192 US20040076636A1 (en) 1993-05-07 2003-07-02 HIV immunogenic complexes
PCT/US2004/020757 WO2005019248A1 (en) 2003-07-02 2004-06-28 Hiv immunogenic complexes

Publications (2)

Publication Number Publication Date
JP2007534615A true JP2007534615A (ja) 2007-11-29
JP2007534615A5 JP2007534615A5 (enExample) 2010-11-04

Family

ID=34216272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006517744A Pending JP2007534615A (ja) 2003-07-02 2004-06-28 Ｈｉｖ免疫原性複合体

Country Status (5)

Country Link
US (1) US20040076636A1 (enExample)
EP (1) EP1638996A1 (enExample)
JP (1) JP2007534615A (enExample)
CA (1) CA2530821A1 (enExample)
WO (1) WO2005019248A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025276A2 (en) * 2005-08-25 2007-03-01 Government Of The United States Of America, As Represented By The Secretary Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies
CA2626257A1 (en) * 2005-10-17 2007-04-26 Novartis Ag Multiclade hiv vaccines
CN107955815B (zh) * 2017-11-30 2019-06-11 山东兴瑞生物科技有限公司 抗hiv-1基因、该基因的应用、具有该基因的dc疫苗及疫苗制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510246A (ja) * 1993-05-07 1996-10-29 アクゾ・ノベル・エヌ・ベー Ｈｉｖ免疫原性複合体
WO2001027294A1 (en) * 1999-10-08 2001-04-19 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US20020155121A1 (en) * 1999-10-08 2002-10-24 Devico Anthony Louis Virus coat protein/receptor chimeras and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510246A (ja) * 1993-05-07 1996-10-29 アクゾ・ノベル・エヌ・ベー Ｈｉｖ免疫原性複合体
WO2001027294A1 (en) * 1999-10-08 2001-04-19 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US20020155121A1 (en) * 1999-10-08 2002-10-24 Devico Anthony Louis Virus coat protein/receptor chimeras and methods of use

Also Published As

Publication number Publication date
CA2530821A1 (en) 2005-03-03
EP1638996A1 (en) 2006-03-29
US20040076636A1 (en) 2004-04-22
WO2005019248A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
US6258599B1 (en) Compositions and methods for treating viral infections
US5166050A (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
JPH08510246A (ja) Ｈｉｖ免疫原性複合体
KR920008744B1 (ko) Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
JPH02160800A (ja) ヒト免疫不全ウイルス（ＨＩＶ）ｅｎｖ‐コードペプチド
WO1991004273A2 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
EP1425036A2 (en) Virus coat protein/receptor chimeras and methods of use
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
US6083504A (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1)
WO1989005821A1 (en) Hiv-related antigens and antibodies
US6248574B1 (en) Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
KR920001772B1 (ko) 포유류 중의 HIV-억제 항체 유도성 사람 면역 결핍 바이러스(HIV) env-암호화된 펩타이드
WO1989005820A1 (en) Hiv-related antigens and antibodies
WO2005019248A1 (en) Hiv immunogenic complexes
AU2006200454B2 (en) Compositions and methods for treating viral infections
AU6655300A (en) Compositions and methods for treating infections
AU2006200455A1 (en) Compositions and methods for treating viral infections
AU2004208648A1 (en) Compositions and methods for treating infections
HK1023371B (en) Compositions and methods for treating viral infections
MXPA99003380A (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100916

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101130